Clinical Trial Protocol Registry
A Study of CellCept (Mycophenolate Mofetil) in Heart Transplant Patients.
- Protocol number:
- Hoffmann-La Roche
- Company division:
- Official Scientific Title:
- A randomized, open-label study to evaluate pharmacokinetic variability of CellCept in association with cyclosporine and corticosteroids in primary orthotopic heart transplant patients
- Brief summary:
- This study will evaluate the pharmacokinetic variability (in terms of AUC) of CellCept in association with cyclosporine and corticosteroids, in primary orthotopic heart transplant patients. Within 72 hours of transplantation, patients will be randomized to one of 2 groups; one group will remain on a fixed dose of CellCept for 3 months, and the other will have their dose adjusted in order to maintain an AUC of mycophenolate mofetil within a target range. CellCept treatment (plus cyclosporine and corticosteroids) will continue for a further 9 months. The anticipated time on study treatment is 3-12 months, and the target sample size is < 100 individuals. Target sample size is 54.
- Study phase:
- Study type:
- Interventional; Treatment; Randomized; Open Label; Parallel; Pharmacokinetics study
- Heart Transplantation
- Primary outcome:
- Pharmacokinetics:AUC 0-12 of mycophenolic acid. Efficacy: Acute rejection rate; allograft artery disease incidence; overall survival.
- Key secondary outcomes:
- Safety: AEs; opportunistic infection; malignancy.
- Inclusion criteria:
- adult patients, 18-65 years of age;
- undergoing primary orthotopic heart transplantation.
- Exclusion criteria:
- recipients of previous or multiple organ transplant;
- patients who have previously received CellCept;
- patients with malignancies or history of malignancy, except successfully treated basal or squamous cell cancer of the skin.
- Males or Females
- Age limits:
- Min: 18 years Max: 65 years
- Accepts healthy volunteers:
- Anticipated start date:
- July, 2002
- Trial registration date:
- Date last updated:
For more information on a specific Roche trials in your country location, please contact your local Roche affiliate nearest you.
- Go on the URL link- http://www.roche.com and click on the Roche Worldwide tab on the top of the page to locate the country nearest you for contact information.
Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the global studies, please have your healthcare provider contact us and they will be provided with the relevant clinical trial information.
For US or global trials with US sites only, please contact the Trial Information Support Line (TISL)
- 1-888-662-6728 Monday to Friday (6am to 3pm PST)